Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
February 22 2021 - 5:15PM
Enochian BioSciences, a company focused on gene-modified cellular
and immune therapies in infectious diseases and cancer, today
announced that it will be making a company presentation to
investors at the upcoming H.C. Wainwright Global Life Sciences
Conference.
Executive Vice Chair Dr. Mark Dybul will provide
an overview of the company’s progress, including its innovative
HIV, Hepatitis B and Oncology platforms. The presentation will be
available on-demand for conference attendees beginning at 7 am
Eastern on Tuesday, March 9, 2021, and also will be available on
the Enochian BioSciences website under the Investors/Media section
in Events and Presentations.
On March 10, Dr. Dybul and Chief Financial
Officer Luisa Puche will be participating in live, virtual
one-on-one meetings with investors who are registered to attend the
conference.
More information on the conference may be found
at H.C. Wainwright’s conference website.
About Enochian BioSciences
Inc.Enochian BioSciences is a biopharmaceutical company
dedicated to identifying, developing, manufacturing, and
commercializing gene-modified cell therapy. Our gene-modified cell
therapy platform can be applied to multiple indications including
HIV/AIDS, HBV and Oncology.
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Enochian’s most recent Annual Report on Form 10-K filed
with the SEC. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Enochian undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2024 to May 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From May 2023 to May 2024